Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26M
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
9.22M
-
Shares change
-
+9.22M
-
Total reported value, excl. options
-
$139M
-
Value change
-
+$139M
-
Number of buys
-
24
-
Price
-
$15.19
Significant Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q1 2021
24 filings reported holding LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share as of Q1 2021.
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.22M shares
of 26M outstanding shares and own 35.45% of the company stock.
Largest 10 shareholders include Novo Holdings A/S (3.33M shares), Redmile Group, LLC (2.82M shares), Nicholas Investment Partners, LP (815K shares), Nantahala Capital Management, LLC (381K shares), Monashee Investment Management LLC (265K shares), MILLENNIUM MANAGEMENT LLC (226K shares), AXA S.A. (220K shares), SPHERA FUNDS MANAGEMENT LTD. (214K shares), Artal Group S.A. (200K shares), and Falcon Edge Capital, LP (150K shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.